A study involving Italian
research into engineering immune cells to target blood cancer is
gaining widespread attention for potentially being a turning
point in cancer therapy.
The study, which was presented in Washington during the
annual meeting of the American Association for the Advancement
of Science (AAAS), focuses on a method which reprograms the
body's T-cells to fight cancer.
It has been widely picked up in the British media, with The
Times highlighting that even some veteran cancer researchers
view the findings as "revolutionary".
The Times underlines the crucial role played by an Italian
team in Milan's San Raffaele hospital, quoting hematology expert
Chiara Bonini.
British papers reported that in one trial, about 94% of
participants with acute lymphoblastic leukaemia, who would
usually only have months to live, saw their symptoms clear up.
The therapy involves taking white blood cells from patients
and genetically modifying them to act as killer-cancer cells.
ALL RIGHTS RESERVED © Copyright ANSA
